Does initiation of ACEi and ARB help in advanced CKD? Check out the VA by Dr Nikhil John
FLOZINATing to the Future- Long Term Effects of Empagliflozin in Patients with CKD
Making Kidney Health a Global Priority
Heart-burn and Kidney Churn
The KDIGO CKD 2024 Guidelines Part 1: Evaluation and Risk Stratification
KDIGO CKD GUIDELINES - VISUAL ABSTRACT
Check out the TOP 10 takeaways from KDIGO - CKD guidelines on evaluation of people with or at risk of CKD by NSMC Intern Stephanie Torres
🤔 Does BP lowering matter for the kidneys after all?
Intensive BP Control in Patients with CKD and Risk for Adverse Outcomes (Ku, JASN 2023)
🤔 Coffee and the kidneys
CYP1A2 Genetic Variation, Coffee Intake, and Kidney Dysfunction (Mahdavi, JAMA Network Open 2023)
🤔 Improving decision making in CKD
Effectiveness of an Intervention to Improve Decision Making for Older Patients With Advanced Chronic Kidney Disease (Ladin, Annals Int Med 2023)
🤔 Screening for albuminuria is cost-effective
Population-Wide Screening for Chronic Kidney Disease: A Cost-Effectiveness Analysis (Cusick, Annals Int Med 2023)
🤔 RASi + diuretics better than RASi + CCB in CKD?
A nationwide cohort study comparing the effectiveness of diuretics and calcium channel blockers on top of renin-angiotensin system inhibitors on chronic kidney disease progression and mortality (Faucon, Kidney International 2023)
🤔 A digital intervention to increase physical activity in CKD
Evaluating the effect of a digital health intervention to enhance physical activity in people with chronic kidney disease (Kidney BEAM): a multicentre, randomised controlled trial in the UK (The EMPA-KIDNEY Collaborative Group The Lancet Digital Health 2024)
🤔 EMPA KIDNEY analysis by CKD diagnosis
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial (The EMPA-KIDNEY Collaborative Group The Lancet 2023)
🤔 EMPA Kidney sub-group analysis by DM and ACR status
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial (The EMPA-KIDNEY Collaborative Group 2023)
🤔 Albuminuria reduction drives Finerenone's kidney benefit
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes (Agarwal et al, Annals IM 2023)
